Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency
Open accessAbstract
There is accumulating evidence that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Herein, to remodel tumor immune microenvironment and elicit synergistic antitumor effects, lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated combinational therapy provided a benign regulation on tumor microenvironment through activation of tumor infiltrating T lymphocytes and natural killer cells, promotion of cytokines secretion of IFN-γ and IL-12, and down-regulation of immunosuppressive myeloid-derived suppressor cells, cytokine IL-10 and TGF-β. ATRA/DOX/IL-2 co-loaded dHMLB demonstrated significant tumor growth and metastasis inhibition, and also exhibited favorable biodegradability and safety. This nanoplatform has great potential in developing a feasible strategy to remodel tumor immune microenvironment and achieve enhanced antitumor effect.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Animals treated with formulations containing doxorubicin, ATRA, and IL-2 were the ones with the most effective tumor growth inhibition and decreased metastasis.
“Animals treated with formulations containing the three agents were the ones with the most effective tumor growth inhibition and decreased metastasis.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [23]
ATRA was effective in differentiating myeloid-derived suppressor cells, and in synergy with doxorubicin, contributed to increase the number of dendritic cells at the tumor site; IL-2 facilitated the proliferation of CD8+ T cells at the tumor site to promote effective tumor killing.
“ATRA was effective in differentiating myeloid-derived suppressor cells, and in synergy with doxorubicin, contributed to increase the number of dendritic cells at the tumor site; IL-2 facilitated the proliferation of CD8+ T cells at the tumor site to promote effective tumor killing.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 59 · Cited by 197
- Authors
- Kong, M., Tang, J., Qiao, Q., Wu, T., Qi, Y., Tan, S., Gao, X., & Zhang, Z.
- Affiliations
- Huazhong University of Science and Technology (CN)
- China Three Gorges University (CN)
- Corresponding author
- Zhang, Zhiping
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2017
- Volume
- 7
- Issue
- 13
- Pages
- 3276-3292
- ISSN
- 1838-7640 (ISSN-L)
- PMC
- PMC5595131
- OpenAlex
- W2739954294
- Cited by
- 197
- References
- 59
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 25 · 2021: 22 · 2020: 30 · 2019: 25 · 2018: 17 · 2017: 2
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Theranostics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81373360, 81673374)
- Fundamental Research Funds for the Central Universities (2016YXMS138, 2015ZDTD048)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- hollow mesoporous silica nanoparticles, biodegradable nanoparticles, tumor microenvironment, chemoimmunotherapy, all-trans retinoic acid, doxorubicin, interleukin-2, lipid coating, myeloid-derived suppressor cells, T cells, natural killer cells, interferon-gamma, IL-12, IL-10, TGF-beta, metastasis suppression, nanoparticle drug delivery
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Antineoplastic Agents, Biocompatible Materials, Dendritic Cells, Disease Models, Animal, Doxorubicin, Humans, Immunity, Interleukin-2, Lipid Bilayers, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasm Metastasis, Silicon Dioxide, Tissue Distribution, Porosity, Cytokines, Cell Line, Tumor, Nanoparticles, Tumor Microenvironment, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
